Malvern’s Uniquity Bio Reports Phase 2 Results for Solrikitug in Eosinophilic Esophagitis

Published · 3 min read · Greater Philadelphia
Malvern’s Uniquity Bio Reports Phase 2 Results for Solrikitug in Eosinophilic Esophagitis

 

Uniquity Bio, a Malvern, Pennsylvania-based clinical-stage company focused on immunology and inflammation, reported topline results from its Phase 2 ALAMERE trial of solrikitug in eosinophilic esophagitis (EoE), the company announced on November 17, 2026. The investigational antibody met both of the trial’s co-primary endpoints at all three doses tested, and Uniquity plans to begin a pivotal Phase 3 trial in the first quarter of 2027.

“We believe these data add to the growing body of evidence that TSLP plays a central role in EoE, and we look forward to beginning our pivotal Phase 3 trial in early 2027,” said Will Kane, CEO of Uniquity.

Inside the ALAMERE Results

EoE is a chronic allergic inflammation of the esophagus that can make swallowing and eating difficult and cause food to become stuck. It affects an estimated 470,000 people in the U.S., according to the release, and its prevalence has risen about fivefold since 2009. Over time, the disease can scar and narrow the esophagus.

The randomized, double-blind, placebo-controlled ALAMERE trial tested three doses of solrikitug (125 mg, 250 mg, and 500 mg) in adults with EoE, given as an injection under the skin every four weeks. Solrikitug is a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP), a protein that triggers allergic inflammation.

At week 24, 69% to 76% of patients across the three doses reached histologic remission, meaning low levels of the immune cells that drive EoE in esophageal tissue, after accounting for placebo. Solrikitug also reduced difficulty swallowing, measured by the Dysphagia Symptom Questionnaire, by 8.8 to 12.6 points more than placebo. Uniquity also reported improvements in key secondary endpoints, including endoscopic and tissue-level disease measures and the number of days without swallowing difficulty. The company says solrikitug was well tolerated.

Dr. Evan Dellon, professor of medicine and director of the Center for Esophageal Diseases and Swallowing at the University of North Carolina School of Medicine, was a principal investigator in the study:

“EoE can be a profoundly difficult disease to live with, and many patients are unable to adequately control their symptoms with the treatments that are currently available. If these results are confirmed in a pivotal trial, I think solrikitug could offer substantial benefit for the treatment of EoE, while also potentially offering significant convenience through an extended dosing interval.”

What’s Next

Uniquity is following trial participants through 52 weeks to assess how long the effects last and to monitor safety. Full results will be presented at a future medical meeting.

The company says its end-of-Phase 2 discussions with the U.S. Food and Drug Administration (FDA) indicated that a single pivotal Phase 3 trial, together with ALAMERE as supporting evidence, could support a Biologics License Application (BLA).

Uniquity is also nearing completion of Phase 2 trials of solrikitug in asthma and chronic obstructive pulmonary disease (COPD). It is also exploring combination or bispecific versions that pair solrikitug with other inflammatory targets.

About Uniquity Bio

Uniquity Bio is backed by Blackstone Life Sciences and develops treatments for immunology and inflammation. It in-licensed solrikitug from Merck and is developing it for respiratory and gastrointestinal conditions. The company has offices in Malvern, Pennsylvania, and San Diego.

MEDIA CONTACT:

Sam Brown Inc. Healthcare Communications

Audra Friis, [email protected], (917) 519-9577​​

Source: Uniquity Bio, https://www.uniquity.com/uniquity-announces-clinically-meaningful-positive-topline-results on November 17, 2026. Republished with credit to the original author. Read the original article.